The
Food and Drug Administration will not support a New Drug Application
for Sunesis Pharmaceuticals Inc.’s (Nasdaq: SNSS) vosaroxin to treat acute
myeloid leukemia. Shares of the biopharmaceutical plummeted $2.51 to close at $0.96.
FDA will not approve Sunesis’ NDA for vosaroxin
July 24, 2015 at 11:33 AM EDT
